Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers

Journal of Clinical Pharmacology

Volumn 36, Issue 12, 1996, Pages 1161-1168

  Shum, Linyee ^a,c   Pieniaszek Jr , Henry J ^a   Robinson, Cynthia A ^a   Davidson, Anna F ^a   Widner, Paul J ^a,d   Benedek, Irma H ^a   Flamenbaum, Walter ^b  

^a DUPONT COMPANY   (United States)

^b Pharmaceutical Evaluation Services   (United States)

^c Quest Pharmaceutical Services   (United States)

^d Du Pont Merck Pharmaceutical Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; IBUPROFEN; MORACIZINE; PARACETAMOL; PHENOTHIAZINE DERIVATIVE;

ADULT; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; STEADY STATE; VERTIGO;

EID: 0030469876     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04171.x     Document Type: Article

References (34)

1. Mann HJ: Moricizine: a new Class 1 antiarrhythmic. J Clin Pharmocol 1990;9:842-852.
2. Howrie DL, Pieniaszek HJ, Fogoros RN, Juhl RP, Schary WL, Whitney CC, Dittert LW: Disposition of moracizine (Ethmozine) in healthy subjects after oral administration of radiolabelled drug. Eur J Clin Pharmacol 1987;32:607-610.
3. Piotrovskii VK, Romina NN, Merkulova IN, Kurbanov RD, Metelitsa VI, Mazar NA: Bioavailability of ethmozine with oral administration [English translation]. Khimiko-Farmatsevticheskii Zhurnal 1983;221:912-916.
4. Benedek IH, Davidson AF, Pieniaszek HJ: Enzyme induction by moricizine: time course and extent in healthy subjects. J Clin Pharmacol 1994;34:167-175.
5. Pieniaszek HJ, Davidson AF, Benedek IH: Effect of moricizine on the pharmacokinetics of single-dose theophylline in healthy subjects. Ther Drug Monit 1993;15:199-203.
6. Chaffman M, Brogden RN: Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 1985;29:387-454.
7. Pieper RW: Bioavailability of diltiazem. Clin Pharmacy 1982;1:204-205.
8. Hermann PH, Rodger SD, Remones G, Thenot JP, London DR, Morselli PL: Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol 1983;24:349-352.
9. Rovei V, Gomeni R, Mitchard M, Larribaud J, Blatrix C, Thebault JJ, Morselli PL: Pharmacokinetics and metabolism of diltiazem in man. Acta Cardiologica 1980;35:35-45.
10. Bottorff MB, Lalonde RL, Kazierad DJ, Hoon TJ, Tsiu SJ, Mirvis DM: The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine, Pharmacotherapy 1989;9:315-321.
11. Hermann DJ, Krol TF, Dukes GE, Hussey EK, Danis M, Han Y-H, et al: Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol 1992;32:176-183.
12. Tateishi T, Ohashi K, Sudo T, Sakamoto K, Toyosaki N, Hosoda S, et al: Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol 1989;29:994-997.
13. Tateishi T, Nakashima H, Shitou T, Kumagai Y, Ohashi K, Hosoda S, Ebihara A: Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmcol 1989;36:67-70.
14. Brockmöller J, Neumayer H-H, Wagner K, Weber W, Heinemeyer G, Kewitz H, Roots I: Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990;38:237-242.
15. Adebayo GI, Akintonwa A, Mabadeje AFB: Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. Eur J Clin Pharmacol 1989;37:127-131.
16. Nafziger AN, May JJ, Bertino JS: Inhibition of theophylline elimination by diltiazem therapy. J Clin Pharmacol 1987;27:862-865.
17. Kazierad DJ, Lalonde RL, Hoon TJ, Mirvis DM, Bottorff MB: The effect of diltiazem on the disposition of encainide and its active metabolites. Clin Pharmacol Ther 1989;46:668-673.
18. Whitney CC, Weinstein SH, Gaylord JC: High-performance liquid chromatographic determination of ethmozin in plasma. J Pharm Sci 1981;70:462-463.
19. Kansas City Analytical Services (KCAS): Analytical Method Report #0205PL-03. Shawnee, MO: KCAS, 1987.
20. Gibaldi M, Perrier D: Pharmacokinetics. Second Edition. New York: Marcel Dekker, 1982;211-218.
21. Carrum G, Egan JM, Abernethy DR: Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine. Clin Pharmacol Ther 1986;40:140-143.
22. Bauer LA, Stenwall M, Horn JR, Davis R, Opheim K, Greene L: Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther 1986;40:239-242.
23. Renton KW: Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985;34:2549-2553.
24. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot J-P, Maurel P: Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990;18:711-719.
25. Pieniaszek HJ, Chaney JE, Sigvardson KW, Davidson AF, Whitney CC, Gaylord JC, et al: Qualitative and quantitative aspects of moricizine metabolism (abstract). Presented at the Third North American Meeting of the International Society for the Study of Xenobiotics, San Diego, October 21-25, 1990;18(42).
26. Vikhlyaev YI, Zherdev VP, Gritsenko AN, Ermakova ZI: Features of ethmozine metabolism. Farmakol Toksikol 1977;40:19-22.
27. Hashem HM: Metabolism of ethmozin by rat liver microsomes (Masters of Science thesis). Pittsburgh: University of Pittsburgh, 1984.
28. King S-YP, Powel RJ, Wong YN, Davidson AF, Vincent DR, Quon CY, Pieniaszek HJ: Effects of multiple doses of moricizine hydrochloride on its pharmacokinetics and hepatic microsomal enzymes in rats. Res Commun Chem Pathol Pharmacol 1992;75:259-274.
29. Montamat SC, Abernethy DR: N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. Br J Clin Pharmacol 1987;24:185-189.
30. Hung J, Hackett PL, Gordon SPF, Ilett KF: Pharmacokinetics of diltiazem in patients with unstable angina pectoris. Clin Pharmacol Ther 1988;43:466-470.
31. Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Williams RL, Giacomini KM: The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 1989;46:408-419.
32. Yabana H, Nagao T, Sato M: Cardiovascular effects of the metabolites of diltiazem in dogs. J Cardiovasc Pharmacol 1985;7:152-157.
33. Narita H, Otsuka M, Yobana H, Nagao T: Hypotensive response of spontaneously hypertensive rats to centrally administered diltiazem and its metabolites: in relevance to the hypotensive action by oral administration. J Pharmacobiodynamics 1986;9:547-553.
34. Schoemaker H, Hicks PE, Langer SZ: Calcium channel receptor binding studies for diltiazem and its major metabolites: functional correlation to inhibition of portal vein myogenic activity. J Cardiovasc Pharmacol 1987;9:173-180.